Published: January 2020
Prefilled syringes present an attractive packaging option that doubles as an easy-to-use drug delivery device, and a product life cycle management tool. Consequently, they have become indispensable within the modern healthcare industry
Roots Analysis has announced the addition of “Prefilled Syringes Market (5th Edition), 2020-2030” report to its list of offerings.
Various factors, such as rise in prevalence of chronic disorders, growing preference for self-injection, anticipated growth of biologics (including vaccines) and biosimilars markets, potential applications in pen-injectors and autoinjectors, and the increasing focus on the prevention of needlestick injuries, are likely to drive growth within the prefilled syringes market.
To order this 550+ page report, which features 150+ figures and 290+ tables, please visit this link
100 prefilled syringes are presently available / under development
Around 70% of these products have glass barrels. It is worth mentioning that majority (16) of the plastic barrel syringes are fabricated using cyclo olefin polymer.
Around 30 companies claim to manufacture add-on / integrated syringe safety products
Examples of players that manufacture add-on safety devices include (in alphabetic order, no selection criteria) Alfa Corpuscles, Biocorp, Credence Medsystems, Nemera, Schreiner Medipharm and Tip-Top.
In order to gain competitive edge in the market, manufacturers are actively engaged in developing patient friendly products
The report features a detailed competitiveness analysis of the various prefilled syringes, taking into consideration the supplier power (based on the employee size of developer / manufacturer and their respective annual revenues) and key product specifications, such as number of chambers in the barrel, number of needle systems, volume of the barrel, technological advancement / user-friendliness and other distinguishing features.
Close to 90 drugs have been approved in combination with prefilled syringes, over the last seven years
Interestingly, majority (53%) of the abovementioned combination products are antibody-based drug candidates. Currently, the next most popular class of therapeutics is vaccines, representing more than 15% of approved prefilled syringe combination products.
110+ clinical candidates are likely to be developed in combination with prefilled syringes in future
The report features insights on the likelihood of over 250+ marketed products and pipeline candidates, being developed in combination with prefilled syringes. Further, we identified 100+ innovator companies that are likely to enter into partnership with prefilled syringe manufacturers in the foreseen future
Currently, the big pharma focus is on developing prefilled combination products for autoimmune disorders
Insights on the initiatives of the top 20 pharmaceutical companies, highlighting their present priorities in terms of therapeutic areas and type of drug product to be developed in combination with prefilled syringes, are available in the full report.
By 2030, prefilled syringes of vaccines and peptide drugs are likely to capture around 40% of the market share
On the other hand, revenues from the sales of prefilled syringe combination products of small molecule and antibody-based drugs, are estimated to grow at annualized rates of 8% and 5.9%, respectively.
To request a sample copy / brochure of this report, please visit this link
The financial opportunity within the prefilled syringes market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom, over time, the demand for prefilled syringes has increased in the developing geographies as well, particularly within the BRICS nations. The report includes detailed transcripts of discussions held with the following experts:
The research covers profiles of key players (listed below), featuring an overview of the companies, their financial information (if available), information on their product portfolio, recent developments and an informed future outlook.
For additional details, please visit
or email firstname.lastname@example.org
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES